tbuckley/cabot-search huggingface dataset:
Prognostic impact of RNA expression profile (EP) in the phase III DECISION trial for patients with advanced radioactive-iodine refractory differentiated thyroid cancer (DTC)
Authors: I. Matos, F. Mancuso, C. Iglesias, P. Nuciforo, C. Zafón, H.G. Palmer, Z. Ogbah, L. Muños, G. Villacampa Javierre, C. Peña, M.S. Brose, M. Schlumberger, A. Vivancos, J. Capdevila
Journal: Annals of Oncology (2017)
The Most Beautiful People
Authors: Mayra B. C. Maymone, Hind H. Neamah, Eric A. Secemsky, Roopal V. Kundu, Dana Saade, Neelam A. Vashi
Journal: JAMA Dermatology (2017)

mild liver enzyme elevations are common postinfection.Clinically apparent liver injury from terbinafine treatment occurs in 1 per 50 000 to 120 000 cases. 6 Asymptomatic elevations in serum aminotransferases are found in less than 1% of patients, which typically self-resolve without discontinuing therapy.We recommend baseline transaminase monitoring.However, routine laboratory monitoring during systemic therapy (12 weeks or less) for onychomycosis in healthy children may be unnecessary owing to low incidence of clinically significant adverse effects, costs of laboratory tests, workup of spurious laboratory abnormalities, and patient discomfort.This study is limited by its generalizability, small sample size, and retrospective nature.Larger, prospective studies evaluating the safety profile in pediatric patients are needed to detect the rare but serious adverse effects that could occur during therapy and work toward FDA label changes for a pediatric onychomycosis indication.
Difficulties in Defining and Measuring Cancer-Related Fatigue—Reply
Authors: Karen M. Mustian, Luke J. Peppone, Suzanne M. Miller
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Reply: Probable imported rather than autochthonous Plasmodium vivax cases in Italy
Authors: G Rezza, D Boccolini, M Menegon, R Romi
Journal: Eurosurveillance (2012)

Preview this article: Reply: Probable imported rather than autochthonous Plasmodium vivax cases in Italy, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/17/50/art20339-en-1.gif
Land-Locked Developing Countries and Their Infrastructural Challenges in Contributing to Global Ethics: A Zimbabwe Case Study
Authors: Nahal Haghbin, Sithembile Ruzario, Paul Ndebele, Teck Chuan Voo
Journal: The American Journal of Bioethics (2017)

This article refers to:A Question of Social Justice: How Policies of Profit Negate Engagement of Developing World Bioethicists and Undermine Global Bioethics
Comparison of an FAP-targeted, CD137 activating DARPin drug candidate with a non-targeted, CD137 activating antibody in a human PBMC transplanted HT-29 mouse tumor model.
Authors: Julia Hepp, Alexander Link, Ulrike Fiedler, Christian Reichen, Clara Metz, Alexander Titz, Ivana Tosevski, Laurent Juglair, Patricia Schildknecht, Yvonne Kaufmann, Simon Fontaine, Ralph Bessey, Zita Arany, Christof Zitt, Keith M. Dawson, Daniel Steiner, Dan Snell, Victor Levitsky, Michael T. Stumpp
Journal: Journal of Clinical Oncology (2017)

e14626 Background: Urelumab (BMS-663513) is a humanized monoclonal antibody binding to CD137 which, upon Fc-clustering, leads to activation of T-cells. Urelumab is currently in Phase 2 clinical development and has been reported to cause significant hepatotoxicities (around 15% Grade ≥2 ALT and AST elevation) when given as infusion every 3 weeks at doses ≥0.3 mg/kg. Currently ongoing clinical trials report decreased systemic toxicity but limited efficacy at lower doses of urelumab. We hypothesized that more effective triggering of CD137 without associated systemic toxicity may be achieved by targeting a CD137 agonistic engager without Fc to fibroblast activation protein (FAP) which is abundantly expressed in the stroma of many solid tumors. To achieve this, a targeted molecule belonging to the DARPin family of binding proteins was composed of one FAP- and two CD137-binding domains in a “beads on a string” format and tested in a mouse model with human PBMCs. Methods: Human PBMCs were used to reconstitute the immune system in NOG mice implanted subcutaneously with HT-29 human colon cancer cells. Mice were monitored for survival, body weight, and tumor size during the treatment phase of two weeks. Results: None of the mice in the control group died and no significant body weight loss was observed. Six of ten (60%) mice in the CD137 antibody group showed strong signs of graft vs. host disease and either died or reached the termination criterion of ≥20% body weight loss and were sacrificed. One of 30 (3%) mice died in the DARPin drug candidate groups but none of the animals showed body weight loss of ≥20% (p &lt; 0.001, Log-rank test). Tumor growth inhibition was comparable for all treatment groups (around 20-30% at Day 18, p &lt; 0.05 vs. control, Mann Whitney Test). Conclusions: This study confirms the hypothesis that systemic toxicities caused by the urelumab mode of action can be circumvented by FAP-targeting of a CD137 agonistic DARPin drug candidate while achieving comparable tumor growth inhibition. Consequently, higher clinical doses of tumor stroma-targeted agonistic DARPin drug candidates might be possible, and may result in stronger tumor growth inhibition.
Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM).
Authors: Cyrille Touzeau, Asher Alban Akmal Chanan-Khan, Andrew Warwick Roberts, Amit Agarwal, Thierry Facon, Daniel Lebovic, Philippe Moreau, David E Darden, Lura J Morris, Jeremy A Ross, Ahmed H. Salem, Wijith Munasinghe, Ming Zhu, Joel Leverson, Sari H. Enschede, Rod Humerickhouse, Simon J Harrison
Journal: Journal of Clinical Oncology (2015)

8580 Background: The anti-apoptotic proteins BCL-2 and MCL-1 promote MM cell survival. BTZ can inhibit MCL-1 activity by elevating the MCL-1 antagonist, NOXA. Venetoclax (VEN) is a selective, orally bioavailable, small-molecule BCL-2 inhibitor, which enhances BTZ efficacy in MM xenograft models. This Ph 1 study evaluates VEN with BTZ and Dex in patients (pts) with R/R MM. Methods: Objectives include safety, PK, preliminary efficacy, and MTD of VEN with BTZ and Dex. Pts received VEN (50-500 mg PO daily) in cycles (C) 1-11 per designated dose escalation (DE) cohorts (continual reassessment); BTZ (1.3 mg/m2SC, days [D] 1, 4, 8, 11) and Dex (20 mg PO, D1, 4, 5, 8, 9, 11, 12) in C1-8 (21D), BTZ+Dex D1, 8, 15, 22 in C9-11 (35D), and VEN alone ≥ C12. Results: 32 pts were enrolled as of 12/18/2014: median age 65; 12/20 F/M. 12 were ISS stage I, 7 stage II, 10 stage III. Median (range) prior therapies: 5 (1–15). 26 pts received prior BTZ (10 refractory), 26 had prior lenalidomide, and 20 auto-HSCT. AEs in ≥ 20% pts: constipation (41%), diarrhea (38%), peripheral edema (28%), thrombocytopenia (31%), peripheral neuropathy (28%), insomnia (28%), dyspnea (25%), anemia (22%). Grade 3/4 AEs (≥10%): thrombocytopenia (25%), anemia (13%). 14 pts had SAE: none VEN-related. Reason for discontinuation (D/C; n = 17): PD (n = 14), AEs (n = 2: adenocarcinoma, cardiac and respiratory decompensation), consent withdrawal (n = 1). 3 deaths occurred (due to PD); 1 DLT at 300 mg (cardiac decompensation attributed to Dex). No TLS occurred. Dose-normalized exposure when given with BTZ+Dex (n = 30) was similar to VEN alone. Preliminary efficacy (best response) by BTZ status. Conclusions: Venetoclax with BTZ and Dex has an acceptable safety profile in heavily pretreated MM. This combination targeting BCL-2 and MCL-1 resulted in anti-tumor activity and longer ToS in pts naïve or sensitive to prior BTZ. DE continues at 600 mg. Clinical trial information: NCT01794507. n (%) Refractory (n=10) Sensitive (n=16) Naïve (n=6) sCR 0 1 (6) 0 CR 0 0 2 (33) VGPR 0 2 (13) 1 (17) PR 0 7 (44) 2 (33) MR 1 (10) 0 0 SD 3 (30) 4 (25) 0 PD 4 (40) 1 (6) 1 (17) D/C 2 (20) 1 (6) 0 ORR (sCR+CR+VGPR+PR) 0 10 (63) 5 (83) Median (range) time on study (Tos), months 1.3 (0.3–4.8) 5.0 (0.7–9.5) 5.0 (1.4–9.4)
Effects of the histone deacetylase inhibitor FK228 in improving adenoviral mediated gene expression and suicide gene therapy inhumanTCC-sup bladder cancer
Authors: Weiguo Jian, Ling Li, Kazumasa Matsumoto, Jiang Yu, Christian T. F. Freund, Seth P. Lerner
Journal: Cancer Research (2004)

4579    Introduction : The present study was designed to evaluate the effects of FK228 effects in improving adenoviral mediated gene expression and suicide gene therapy in human bladder cancer in vitro and in vivo.  Material and Methods : TCC-sup (CAR deficient) cells were treated with FK228 and cultured with Ad5GFP. GFP expression was analyzed with the FACS 24 h later. Cytotoxicity of FK228 to TCC-sup cells was examined with the MTT assay after 48 hours of applying of FK228. The Ad5tk were constructed and used in therapeutic assay. After 48 h pre-treated with FK228, cells were transduced with Ad5tk. Ganciclovir (GCV) was added to the media next day and incubated for 72 hours. Number of viable cells at the end of incubation was determined using a standard MTT assay. Apoptotic cells were detected with annexin V-FITC apoptpsis detection kit. CAR status after administered of FK228 at 10 ng/ml and 20 ng/ml for 48 hours was examined with the monoclonal CAR antibody and PE-conjugated secondary antibody, and analyzed with FACS. Expression of E-cadherin was assessed with Western blotting after administered FK228 in TCC-sup cells. Cell immigration was measured with the wound scraped method. To testing FK228 inhibition in TCC-sup cells, the cell invasion chambers were used. To determine the treatment efficacy, subcutaneous TCC-sup tumors were established in nude mice and treated combined Ad5tk/GCV with FK228.  Results : Cells treated with 1ng/ml and 10 ng/ml FK228 for 48 h prior to Ad5GFP infection had a 2.4-fold and 2.6-fold increase in GFP expression. After administered of FK228, the cell growth percentage decreased 30% at 1ng/ml and 71% at 10 ng/ml compared with the control. Effect of FK228 to enhance Ad5tk inhibition on cell viability: FK228 very strongly inhibited cell growth at a dose of 10 ng/ml vs the positive control (Ad5tk/GCV alone) (p = 0.006). The cell survival with10 ng/ml FK228 was 31%. There was a very clear dose responses relationship with treatment of FK228. The cell survival with10 ng/ml FK228 was 31% at 300 MOI. The apoptosis cells were significantly increased by adding FK228 to Ad5TK + GCV. The proportion was 5-fold increase vs control cells (Ad5TK + GCV alone). Expression of CAR induced by FK228: FK228 up-regulated CAR expression 9-fold vs control cells. E-cadherin protein was increased by addition of FK228 in cells. Immigration was significantly inhibited after added FK228 in TCC-sup cells ( p  p  p  Conclusion : Ad5tk suicide gene therapy was improved by FK228 administration,, which may contribute to the up-regulation of CAR and E-caderin expression.
Clinical Significance of Histologic Variants of Bladder Cancer
Authors: Joshua I Warrick
Journal: Journal of the National Comprehensive Cancer Network (2017)

Pathologists have identified many “histologic variants” of bladder cancer (BCA): histologic patterns that differ from conventional urothelial carcinoma (transitional cell carcinoma). Several of these are biologically aggressive, and their identification may aid in clinical decision-making. This article reviews several histologic variants and their value in deciding management of cT1 disease and predicting response to neoadjuvant chemotherapy (NAC). Diagnostic issues are also addressed, such as interobserver variability among pathologists. For example, although stage cT1 conventional urothelial carcinoma is usually managed conservatively, cT1 micropapillary carcinoma has high mortality following conservative management, and early cystectomy may reduce mortality. Similarly, plasmacytoid and small cell cancers are remarkably aggressive, and those diagnosed as stage cT1 at transurethral resection are likely understaged; conservative management thus greatly risks undertreatment. As an example of response, NAC dramatically reduces mortality in patients with small cell BCA, and is thus the standard of care, even in stage cT1 disease. Although identification of histologic variants may inform on optimal management, diagnostic issues challenge their incorporation into clinical practice. For example, interobserver reproducibility is only moderate for the diagnosis of micropapillary BCA. Studies have identified specific histologic issues underlying this diagnostic irreproducibility, and ongoing work aims to remedy this issue. In summary, histologic variants are emerging as potentially useful biomarkers in the management of BCA. Although issues remain unresolved, pathologists and treating physicians will benefit from understanding these variants and their prognostic and therapeutic implications.
Prognostic nomogram for overall survival in previously untreated patients with diffuse large B-cell lymphoma
Authors: Y. Han, Y. Qin, P. Liu, J. Yang, X. He, S. Zhou, L. Gui, S. Yang, C. Zhang, Y. Huang, S. Jiang, Y. Shi, Q. Wang, Y. Sun, Y-K. Shi
Journal: Annals of Oncology (2017)
Controlling the Release of Small, Bioactive Proteins via Dual Mechanisms with Therapeutic Potential
Authors: Prathamesh M. Kharkar, Rebecca A. Scott, Laura P. Olney, Paige J. LeValley, Emanual Maverakis, Kristi L. Kiick, April M. Kloxin
Journal: Advanced Healthcare Materials (2017)

Abstract Injectable delivery systems that respond to biologically relevant stimuli present an attractive strategy for tailorable drug release. Here, the design and synthesis of unique polymers are reported for the creation of hydrogels that are formed in situ and degrade in response to clinically relevant endogenous and exogenous stimuli, specifically reducing microenvironments and externally applied light. Hydrogels are formed with polyethylene glycol and heparin‐based polymers using a Michael‐type addition reaction. The resulting hydrogels are investigated for the local controlled release of low molecular weight proteins (e.g., growth factors and cytokines), which are of interest for regulating various cellular functions and fates in vivo yet remain difficult to deliver. Incorporation of reduction‐sensitive linkages and light‐degradable linkages affords significant changes in the release profiles of fibroblast growth factor‐2 (FGF‐2) in the presence of the reducing agent glutathione or light, respectively. The bioactivity of the released FGF‐2 is comparable to pristine FGF‐2, indicating the ability of these hydrogels to retain the bioactivity of cargo molecules during encapsulation and release. Further, in vivo studies demonstrate degradation‐mediated release of FGF‐2. Overall, our studies demonstrate the potential of these unique stimuli‐responsive chemistries for controlling the local release of low molecular weight proteins in response to clinically relevant stimuli.
Uncovering the diagnostic dermoscopic features of flat melanomas located on the lower limbs
Authors: S. Bassoli, A. Kyrgidis, S. Ciardo, A. Casari, A. Losi, B. De Pace, G. Babino, E. De Col, J. Marchetti Cautela, F. Ferrari, E. Moscarella, A. Lallas, G. Argenziano, G. Pellacani, C. Longo
Journal: British Journal of Dermatology (2017)

Lower limbs represent the second most common site of all melanomas and the first one in females (1,2). Few studies have explored the diagnostic clues helping in the early diagnosis for melanoma on lower limbs (3).

This article is protected by copyright. All rights reserved.
Preclinical testing of a novel regimen of capecitabine (C) in combination with bevacizumab (B) and trastuzumab (T) in a breast cancer xenograft model
Authors: T. A. Traina, B. Higgins, M. Theodoulou, U. Dugan, K. Kolinsky, Y. Zhang, D. Heimbrook, K. Packman, C. Hudis, L. Norton
Journal: Journal of Clinical Oncology (2007)

1049 Background: Mathematical methods applied to xenograft breast cancer models have determined that the maximum impact of C therapy occurs after ∼7 days (7d) of treatment (Norton AACR 2005). The model predicts that doses of C beyond 7d will contribute to toxicity without additional antitumor benefit. The tolerability and anti-tumor activity of C 7d on/7d off (7/7) in female nude mice bearing KPL-4 breast cancer xenografts has been established (SABCS 2006). We now report preclinical models of C7/7 with targeted therapies. Methods: We evaluated the tumor growth inhibition (TGI%) and increase in life span (ILS%) of C7/7 and B with or without T in female nude mice bearing KPL-4, HER2+ breast cancer xenografts. C at maximum tolerated dose (MTD) and ½MTD were tested in combination with conventional doses of the antibodies. Results: C7/7 at MTD is well tolerated in combination with conventional dose B + T. No toxicity was observed at any dose level. The addition of B ± T to C7/7 monotherapy significantly improves TGI%. Survival is significantly prolonged for the combination of C7/7 MTD with B ± T. Comparative results for C7/7 at MTD and ½ MTD are shown in the Table . Additional comparative data will be shown at the meeting. Assessment of ILS% is ongoing for the triplet C7/7 + B + T but has exceeded 463% and &gt;152 days. Conclusions: The improvement in response and survival shown here supports the study of combination C7/7 with B and T. Combinations with B and anti-HER2 therapy will be tested in the clinical, Phase II program at MSKCC. [Table: see text] [Table: see text]
GW28-e0429 Protective Effect of Physcion on Homocysteine-induced Endothelial Dysfunction via Activation of PI3-kinase/Akt- and Ca2+-eNOS-NO Pathway
Authors: Hangji Lyu, Xiaowei Ji, Ziqi Zhou, Mei Zhuang, Qingqing Yang, Songnan Jin, Kyungwoo Cho, Jinfu Wen
Journal: Journal of the American College of Cardiology (2017)
Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia
Authors: Denis E. Reyna, Thomas P. Garner, Andrea Lopez, Felix Kopp, Gaurav S. Choudhary, Ashwin Sridharan, Swathi-Rao Narayanagari, Kelly Mitchell, Baoxia Dong, Boris A. Bartholdy, Loren D. Walensky, Amit Verma, Ulrich Steidl, Evripidis Gavathiotis
Journal: Cancer Cell (2017)
Survival of patients with aromatase inhibitors sensitive, HR+/HER2- metastatic breast cancer treated with a first-line endocrine therapy or chemotherapy in a multicenter national observational study
Authors: E. Jacquet, A. Lardy-Cleaud, B. Pistilli, P. Cottu, S. Delaloge, M. Debled, L. Vanlemmens, G. Anne-Valérie, M. Leheurteur, L. Laborde, W. Jacot, D. Berchery, B. Coudert, J-M. Ferrero, D. Parent, V. Diéras, M. Velten, C. Courtinard, M. Robain, T. Bachelot
Journal: Annals of Oncology (2017)
Efficacy and safety of RGB-02, a proposed biosimilar pegfilgrastim to prevent chemotherapy-induced neutropenia: Results of a randomized, double-blind, phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving docetaxel/doxorubicin
Authors: K. Horvat-Karajz, D. Grecea, M. Smakal, A. Illes, Z. Kahan
Journal: Annals of Oncology (2017)
Wound Dressings: An Advanced Multifunctional Hydrogel‐Based Dressing for Wound Monitoring and Drug Delivery (Adv. Healthcare Mater. 19/2017)
Authors: Bahram Mirani, Erik Pagan, Barbara Currie, Mohammad Ali Siddiqui, Reihaneh Hosseinzadeh, Pooria Mostafalu, Yu Shrike Zhang, Aziz Ghahary, Mohsen Akbari
Journal: Advanced Healthcare Materials (2017)

Wound management is a major global challenge and poses a significant financial burden to the healthcare system. In article 1700718, Mohsen Akbari and co-workers develop an advanced multifunctional dressing (GelDerm) capable of colorimetric measurement of pH, an indicator of bacterial infection, and release of antibiotic agents at the wound site. GelDerm makes wound care easier and less painful to the patient, and more cost-effective for the healthcare system.
Epidemiology of rubella and congenital rubella syndrome in Greece, 1994-2003
Authors: T Panagiotopoulos, T Georgakopoulou
Journal: Eurosurveillance (2004)

In 1993, there was a large epidemic of rubella and congenital rubella syndrome (CRS) in Greece. The epidemiology of rubella and CRS after 1993 is described in this paper using information from surveillance data and published studies and reports. The incidence of rubella fell sharply after 1993, but a smaller outbreak occurred in 1999, mainly in young adults, and four CRS cases (4.0 per 100,000 live births) were recorded. A very high proportion of the child population in Greece are currently vaccinated for rubella, while teenagers are inadequately covered (60-80% in different studies). A substantial proportion of women of childbearing age are susceptible to rubella (10-20% in urban areas). This could lead to local or more extended outbreaks. This situation shows that a comprehensive preventive policy should be implemented.
Effects of neratinib (N) on health-related quality of life (HRQoL) in early-stage HER2+ breast cancer (BC): longitudinal analyses from the phase III ExteNET trial
Authors: S. Delaloge, Y. Ye, D. Cella, M. Buyse, A. Chan, C. Barrios, F.A. Holmes, J. Mansi, H. Iwata, B. Ejlertsen, B. Moy, G. von Minckwitz, S. Chia, M. Gnant, S. Smichkoska, A. Ciceniene, S. Moran, A.H. Auerbach, L. Fallowfield, M. Martin Jimenez
Journal: Annals of Oncology (2017)
Anti-CTGF human recombinant monoclonal antibody pamrevlumab increases resectability and resection rate when combined with gemcitabine/Nab-paclitaxel in the treatment of locally advanced pancreatic cancer patients
Authors: E. Carrier, V. Picozzi, M.J. Pishvaian, K. Mody, J. Winter, J. Glaspy, T. Larson, W.C. Conway, K. Lipson, S. Porter, E. Kouchakji
Journal: Annals of Oncology (2017)